Trials / Completed
CompletedNCT03909698
Antibiotic Dosing in Patients on Intermittent Hemodialysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- University Hospital, Ghent · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The adequacy of the currently used dosing regimen of glycopeptides (vancomycin and teicoplanin) and beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam, ceftazidim) in patients with end-stage kidney disease receiving intermittent hemodialysis is studied by evaluating pharmacokinetics-pharmacodynamics (PK-PD) target attainment. A population pharmacokinetic study is performed to assist the selection of the optimal individualized dose for patients undergoing intermittent dialysis, taking into consideration as many relevant variables as possible.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood and urine sampling | During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals. |
Timeline
- Start date
- 2016-09-15
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
- First posted
- 2019-04-10
- Last updated
- 2022-11-29
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03909698. Inclusion in this directory is not an endorsement.